189 related articles for article (PubMed ID: 19793711)
21. Recent progress in the use of monoclonal antibodies for imaging and therapy.
Monson JR
Curr Opin Gen Surg; 1993; ():334-9. PubMed ID: 7584004
[TBL] [Abstract][Full Text] [Related]
22. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
Ribas A
Oncologist; 2008; 13 Suppl 4():10-5. PubMed ID: 19001146
[TBL] [Abstract][Full Text] [Related]
23. Cancer and immune response: old and new evidence for future challenges.
de la Cruz-Merino L; Grande-Pulido E; Albero-Tamarit A; Codes-Manuel de Villena ME
Oncologist; 2008 Dec; 13(12):1246-54. PubMed ID: 19056856
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of immunostimulatory monoclonal antibodies.
Gray JC; Johnson PW; Glennie MJ
Clin Sci (Lond); 2006 Aug; 111(2):93-106. PubMed ID: 16831129
[TBL] [Abstract][Full Text] [Related]
25. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
Tarhini AA; Kirkwood JM
Curr Opin Mol Ther; 2007 Oct; 9(5):505-14. PubMed ID: 17932815
[TBL] [Abstract][Full Text] [Related]
26. Effect of T-activin therapy on indomethacin modulation of lymphoproliferative response in vitro of melanoma patients.
Stanojević-Bakić N; Vucković-Dekić L; Milosević D; Sasić M
Panminerva Med; 1998 Dec; 40(4):314-8. PubMed ID: 9973828
[TBL] [Abstract][Full Text] [Related]
27. CTLA4-induced splenomegaly and a review of the literature pertaining to autoimmune complications of therapy.
Ezra N; Goltche NB; Hakimian S; Afari A
J Drugs Dermatol; 2010 Nov; 9(11):1432-6. PubMed ID: 21061768
[TBL] [Abstract][Full Text] [Related]
28. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
Comin-Anduix B; Lee Y; Jalil J; Algazi A; de la Rocha P; Camacho LH; Bozon VA; Bulanhagui CA; Seja E; Villanueva A; Straatsma BR; Gualberto A; Economou JS; Glaspy JA; Gomez-Navarro J; Ribas A
J Transl Med; 2008 May; 6():22. PubMed ID: 18452610
[TBL] [Abstract][Full Text] [Related]
29. Anticytotoxic T lymphocyte-associated antigen 4 treatment--can melanoma be cured at the expense of autoimmune disorders?
Lejeune FJ
Melanoma Res; 2006 Oct; 16(5):377-8. PubMed ID: 17013085
[No Abstract] [Full Text] [Related]
30. Modulation of tumor immunity by therapeutic monoclonal antibodies.
Abès R; Teillaud JL
Cancer Metastasis Rev; 2011 Mar; 30(1):111-24. PubMed ID: 21267767
[TBL] [Abstract][Full Text] [Related]
31. Development of monoclonal antibodies for analyzing immune and hematopoietic systems of common marmoset.
Kametani Y; Suzuki D; Kohu K; Satake M; Suemizu H; Sasaki E; Ito T; Tamaoki N; Mizushima T; Ozawa M; Tani K; Kito M; Arai H; Koyanagi A; Yagita H; Habu S
Exp Hematol; 2009 Nov; 37(11):1318-29. PubMed ID: 19715740
[TBL] [Abstract][Full Text] [Related]
32. Tumor immunotherapy in melanoma: on the dawn of a new era?
Wilcox R; Markovic SN
Curr Opin Mol Ther; 2007 Feb; 9(1):70-8. PubMed ID: 17330404
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of advanced or metastatic melanoma.
Cebon J; Gedye C; John T; Davis ID
Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
[TBL] [Abstract][Full Text] [Related]
34. Treatment approaches for advanced cutaneous melanoma.
Stein JA; Brownell I
J Drugs Dermatol; 2008 Feb; 7(2):175-9. PubMed ID: 18335655
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
36. Immunostimulatory monoclonal antibodies for cancer therapy.
Melero I; Hervas-Stubbs S; Glennie M; Pardoll DM; Chen L
Nat Rev Cancer; 2007 Feb; 7(2):95-106. PubMed ID: 17251916
[TBL] [Abstract][Full Text] [Related]
37. High-level expression of a functional humanized anti-CTLA4 single-chain variable fragment antibody in Pichia pastoris.
Cai H; Chen L; Wan L; Zeng L; Yang H; Li S; Li Y; Cheng J; Lu X
Appl Microbiol Biotechnol; 2009 Feb; 82(1):41-8. PubMed ID: 18936937
[TBL] [Abstract][Full Text] [Related]
38. Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients.
Weber JS
Ann Surg Oncol; 2005 Dec; 12(12):957-9. PubMed ID: 16244797
[No Abstract] [Full Text] [Related]
39. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.
Kumpel BM
Vox Sang; 2007 Aug; 93(2):99-111. PubMed ID: 17683353
[TBL] [Abstract][Full Text] [Related]
40. Tremelimumab: a review of development to date in solid tumors.
Tarhini AA
Immunotherapy; 2013 Mar; 5(3):215-29. PubMed ID: 23444951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
